RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
  Inflammatory Bowel Disease
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Sep 15, 2017 - 4:49:58 AM
Research Article
Gastroenterology Channel

subscribe to Gastroenterology newsletter
Latest Research : Gastroenterology

   EMAIL   |   PRINT
Weight loss by targeting satiety hormone

Aug 27, 2011 - 7:40:40 PM , Reviewed by: Dr. Sanjukta Acharya

[RxPG] The number of people who are obese and suffer one or more of its associated health problems (including type 2 diabetes) is escalating dramatically. Researchers are seeking to identify new targets for therapeutics that could limit appetite and thereby obesity. A team of researchers, led by Scott Waldman, at Thomas Jefferson University, Philadelphia, has now uncovered one such potential target by studying the molecular control of appetite in mice.

Guanylyl cyclase 2C (GUCY2C) is a transmembrane receptor that makes cGMP in response to the paracrine hormones guanylin and uroguanylin, which regulate epithelial cell dynamics along the crypt-villus axis. The researchers showed that silencing of GUCY2C in mice disrupts satiation, resulting in hyperphagia. This caused obesity and metabolic syndrome. In the study, Waldman and colleagues found that nutrient intake by mice caused cells in their gut to secrete the precursor of the hormone uroguanylin (prouroguanylin) into the blood. This travelled around the blood and was converted to uroguanylin in a region of the brain known as the hypothalamus, which is well known to be involved in decreasing appetite. The active uroguanylin was then found to bind to proteins on nerve cells known as GUCY2C receptors, triggering a cascade of events that led to decreased food intake.

The uroguanylin-GUCY2C endocrine axis may provide a therapeutic target to control appetite, obesity, and metabolic syndrome.

Publication: Journal of Clinical Investigation doi:10.1172/JCI57925

Funding information and declaration of competing interests: These studies were supported by grants from NIH and Targeted Diagnostics and Therapeutics. Scott A. Waldman is the Chair of the Data Safety Monitoring Board for the C-Cure Trial sponsored by Cardio3 Biosciences and the Chair (uncompensated) of the Scientific Advisory Board to Targeted Diagnostics and Therapeutics Inc., which provided research funding that, in part, supported this work and has a license to commercialize inventions related to this work.
Related Gastroenterology News
4 UCLA stem cell researchers receive CIRM Early Translational grants
Genetics defines a distinct liver disease
Nerve damage may underlie widespread, unexplained chronic pain in children
Colonoscopy cost sharing eliminated for privately insured patients
EASL publishes first comprehensive literature review on the burden of liver disease in Europe
Targeting neurotransmitter may help treat gastrointestinal conditions
NIH launches free database of drugs associated with liver injury
Genetic clues to the causes of primary biliary cirrhosis!
Taxman Foundation pledges $2.5 million to boost training of digestive disease experts
Early introduction of biologic therapy improves Crohn's disease outcomes

Subscribe to Gastroenterology Newsletter

Enter your email address:

 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS MRCP is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in nephrology. She can be reached for corrections and feedback at [email protected]
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online


Online ACLS Certification


    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)